Topic Paragraphs
FDA Lapse in Funding
Mission-critical activities of FDA will continue during the Democrat-led government shutdown. Please use this site as a resource as the Trump Administration works to reopen the government for the American people.
FDA Accomplishments for the American People
Recalls, Market Withdrawals, & Safety Alerts
Alerting you to the latest recalls of potentially unsafe FDA-regulated products gathered from press releases and other public notices. Not all recalls have press releases or are posted on this website.
Oct 10
Raw Bistro Pet Fare Voluntarily Recalls Frozen Beef Entrée Because of Possible Salmonella Health Risk
Animal & Veterinary, Food & Beverages
Oct 10
Ben’s Original™ Issues Voluntary Recall of Select Ben's Original Long Grain White, Whole Grain Brown, and Long Grain & Wild Ready Rice Products Due to Possible Presence of Small Stones from Farm
Food & Beverages
Oct 09
Foodynamics Recalls Raw Dog Barkery, BellePepper Cats, and Kanu Pets Brand Freeze-Dried Pet Treats Because Of Possible Salmonella Contamination
Animal & Veterinary, Food & Beverages
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
FDA Encourages Development of New, Reliable Alternatives to Animal Testing in Sunscreen
FDA strongly encourages companies to continue to develop new, reliable ways to minimize animal testing.
FDA Focuses on Closing the Clinical Trial Reporting Gap for Research Integrity
The FDA is committed to ensuring data transparency by promoting timely registration and reporting of results information to ClinicalTrials.gov.
FDA Advances Drug Development Innovation by Establishing ISTAND as Permanent Qualification Program
ISTAND supports innovative, science-driven approaches that improve drug development and regulatory decision-making.
Recently Published Guidances
Oct 14
CVM GFI #299 -Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs with a New World Screwworm-Related Indication
Animal & Veterinary
Oct 14
Technical Specifications for Submitting Clinical Trial Data Sets for Response Assessments for Treatments of Acute Leukemias
Sep 30
E20 Adaptive Designs for Clinical Trials
Drugs